Track the Alkuri Global Acquisition CORP. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Alkuri Global Acquisition CORP. has published 2 public disclosures. The latest transaction was reported on 19 October 2021 (Acquisition). Among the most active insiders: Williams Rich. Every trade is openly available.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
2 of 2 declarations
ALKURI GLOBAL ACQUISITION CORP. was a U.S.-incorporated special purpose acquisition company (SPAC), formed in Delaware on December 1, 2020. Its original purpose was not to operate an industrial business, but to serve as a public-market acquisition vehicle designed to complete a merger, share exchange, asset acquisition, stock purchase, or similar business combination with one or more operating companies. The company later changed its name in March 2021 and subsequently completed a business combination with Babylon Holdings in October 2021. In other words, Alkuri’s corporate history is best understood as a SPAC lifecycle rather than as a standalone operating franchise. From a market perspective, Alkuri was associated with the NASDAQ under the symbols KURI, KURIU, and KURIW prior to the closing of the transaction. After the combination, the resulting operating platform moved forward under Babylon and its NYSE listing. For investors, especially those tracking SEC Form 4 insider transactions, this matters because Alkuri is primarily relevant as a transaction vehicle and historical issuer, not as a continuing standalone business with its own long-term product revenue base. The company’s core “business” as a SPAC was to raise capital from public investors, hold those proceeds in trust, and identify a target business with attractive growth characteristics. SEC materials describe a management team with significant experience in technology, consumer internet, marketing, and growth-stage company building. That sponsor profile was central to Alkuri’s competitive positioning: in the SPAC market, the edge comes less from proprietary products and more from sourcing credibility, deal execution, capital structure expertise, and the ability to bring a target public efficiently. Geographically, Alkuri was headquartered in Nashville, Tennessee, United States, placing it within the U.S. capital-markets ecosystem that supports SPAC formation and merger execution. Its eventual target, Babylon, operated in digital healthcare with an international footprint, which gave the transaction a cross-border angle and a sector focus in healthcare technology. That context is relevant for francophone investors assessing the company’s legacy filings: Alkuri’s historical significance lies in the public-market path it created for a healthcare-tech business, rather than in a continuing standalone operating model. Key milestones include the company’s incorporation in late 2020, the name change in early 2021, the announcement of the Babylon business combination in mid-2021, and the closing of that transaction in October 2021. As a result, current references to Alkuri in SEC documentation should generally be interpreted through that SPAC and merger lens. In practical terms, Alkuri is a former NASDAQ-listed acquisition vehicle tied to a completed healthcare-sector transaction in the United States, with its present relevance centered on historical disclosures and insider filings rather than active commercial operations.